2024 R&D Insights & Analytics Report
Cycle Times and Success Rates Unveiled
Empower Your Strategy with Comprehensive Benchmarks and Performance Metrics in Biopharmaceutical R&D
WCG’s 2024 R&D Insights & Analytics Report evaluates eight aspects of Research and Development (R&D): investment, productivity, pipeline, cycle time, success, new molecular entity (NME) approvals, ethical pharma sales, and NME product sales. Each section consists of several subtopics that provide specific metrics and indicators of R&D performance and outcomes.
With this report, you can:
- Increase your chances of success and productivity by accessing the most comprehensive and robust database of global R&D performance metrics.
- Optimize your drug development strategy by minimizing white space and maximizing the value of your pipeline. Use KMR’s white space analysis to identify the gaps and delays in your drug development process that increase costs and reduce productivity.
- Compare your pipeline performance across therapeutic areas, modalities, and phases using KMR’s innovative and validated methodology that accounts for success rates, duration, and investment.
- Gain a competitive edge and identify best practices by leveraging KMR’s extensive expertise and insights on the drivers and challenges of drug development.
- Benchmark your drug development performance against the industry standards using KMR’s comprehensive and reliable data.
Report Outline:
- Section 1: R&D Investment
- Section 2: R&D Productivity
- Section 3: Clinical Development Pipeline
- Section 4: Cycle Time
- Section 5: Success
- Section 6: New Molecular Entity Approvals
- Section 7: Value – Ethical Pharma Sales
- Section 8: Value – New Product Sales & NME Product Sales
Purchase the 2024 R&D Insights & Analytics Report
Access proprietary validated performance metrics and benchmarks to elevate your R&D strategy and productivity. The 2024 report (191 pages) can be purchased in its entirety or as individual sections.
Scroll down to view pricing and initiate purchase, or contact us for more information.
| Item | Price |
|---|---|
| Full R&D Insights & Analytics Report (all sections) | $45,000 USD |
| Section: Success | $20,000 USD |
| Section: Cycle Time | $20,000 USD |
| Section: Pipeline, Investment and Productivity | $10,000 USD |
| Section: Value/Approvals | $10,000 USD |
Complete this form to initiate purchase:
What happens next?
- You’ll immediately receive the sample version of the report.
- WCG will contact you to initiate purchase via invoice or ACH/wire transfer.
- Once payment completed, you’ll receive the digital copy of the full report or any individual sections purchased.
Learn More About our Benchmarking Capabilities
KMR, a WCG company, has been working exclusively in the biopharmaceutical R&D industry since 1990 as a leader in benchmarking, analytics, and performance management. Using its extensive peerless datasets and experience, KMR provides data-driven solutions to the most pressing business questions within the industry.